SKAN Reports Robust Growth and Confirms Full-Year Guidance

In the first half of 2026, SKAN Group AG achieved notable growth in order intake and net sales. Orders increased by 16.3% to CHF 247.6 million, while net sales rose by 22.2% to CHF 164.5 million. On a currency-adjusted basis, this represents a 24.0% increase. These achievements support SKAN's confidence in its full-year guidance, which anticipates net sales growth in the high-teens and an EBITDA margin between 13% and 15%.

The performance was driven by the strong demand in the pharmaceutical and biotech industries, particularly in the U.S. SKAN's Equipment & Solutions segment saw a 3.7% rise in order intake, while the Services & Consumables segment experienced a significant 54.6% growth. Overall, profitability improved, with EBITDA increasing from CHF 0.9 million in H1 2025 to CHF 15.3 million.

This growth reflects SKAN's strong market positioning and the robust demand for technologically advanced aseptic production solutions.